A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII.

Trial Profile

A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Aug 2017

At a glance

  • Drugs T-lymphocyte cell therapy (Primary) ; Aldesleukin; Cell therapies; Cyclophosphamide; Fludarabine
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Oct 2016 Status changed from suspended to recruiting.
    • 12 Apr 2016 Planned End Date changed from 1 Sep 2018 to 1 Dec 2019.
    • 12 Apr 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top